"Compounded GLP-1" gets used as a single category in most consumer-facing coverage, but it actually describes products made under two legally distinct frameworks within the Federal Food, Drug, and Cosmetic Act — Section 503A and Section 503B — with meaningfully different scale, oversight, and current legal status. Understanding the distinction explains both how the compounded GLP-1 industry grew so quickly during 2022's shortages and why its legal footing has narrowed so much since.
Section 503A: patient-specific compounding
Section 503A governs traditional compounding by state-licensed pharmacies and physicians, preparing medications for a specific, identified patient based on an individual prescription.[1] 503A pharmacies:
- Compound in response to individual, patient-specific prescriptions — not in bulk, anticipatory batches
- Are licensed and regulated primarily at the state level, through state boards of pharmacy
- Can compound a drug that is "essentially a copy" of an FDA-approved product only under specific circumstances — most commonly when that drug is on the FDA's official drug shortage list
Section 503B: outsourcing facilities
Section 503B governs "outsourcing facilities" — entities that register with the FDA and compound in larger batches for distribution to multiple healthcare providers or facilities, rather than against individual prescriptions.[1] 503B outsourcing facilities:
- Register directly with the FDA and are subject to current Good Manufacturing Practice (cGMP) requirements — a materially higher production standard than 503A
- Can compound from a bulk drug substance only if that substance appears on the FDA's 503B Bulks List (a formal "clinical need" determination) or the compounded drug is on the drug shortage list at the time of compounding, distribution, and dispensing
- Are what most large-scale compounded GLP-1 supply came from at peak production — reportedly around 30% of total U.S. GLP-1 supply in 2024
How the 2022 shortage created the compounded GLP-1 industry under both frameworks
When semaglutide and tirzepatide were added to the FDA drug shortage list in 2022 due to surging demand, both 503A and 503B pathways to legal compounding opened simultaneously — 503A pharmacies could compound "essentially a copy" products under the shortage exemption, and 503B outsourcing facilities could compound from bulk substances under the same shortage-list pathway (since neither drug was, or is, on the formal 503B Bulks List). This dual-pathway opening is what allowed compounded GLP-1 production to scale as quickly and broadly as it did.
Section 503B separately provides for compounding from a bulk drug substance if the drug product compounded from the bulk drug substance is on the FDA drug shortage list at the time of compounding, distribution, and dispensing.
Why both pathways have narrowed since
The shortage designations that enabled both 503A and 503B compounding were removed by the FDA — tirzepatide in October 2024, semaglutide in February 2025 — eliminating the shortage-list pathway for both frameworks.[2] Separately, in April 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which — if finalized — would permanently close even the "clinical need" pathway for 503B outsourcing facilities, regardless of any future shortage designation.[3]
Why 503A and 503B aren't equally affected
The 503B Bulks List exclusion proposal specifically targets Section 503B — it has no independent legal effect on Section 503A pharmacies, which operate under separate statutory authority and were never dependent on the Bulks List mechanism. However, 503A's "essentially a copy" compounding authority was already substantially narrowed when the underlying shortage designations were removed in 2024–2025, meaning both frameworks have lost their primary legal basis for large-scale GLP-1 compounding — through two different, independently operating legal mechanisms.
What remains legally available
503A pharmacies can still compound GLP-1 medications for genuine, documented clinical need outside the "essentially a copy" shortage exemption — for example, a patient with a documented allergy to an excipient in the FDA-approved product, or a dosage form the approved product doesn't offer. This is a narrower, individualized legal basis than the shortage-driven mass compounding of 2022–2024.
The scale difference matters practically, not just legally. 503A's patient-specific, prescription-triggered model cannot replicate the production volume, consistency, or distribution reach that 503B outsourcing facilities provided at peak — meaning even where 503A compounding remains technically legal, it represents a much smaller potential supply than the market saw during the shortage years.
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.